Good afternoon :)
Place Order
Add to Watchlist

Gufic Biosciences Ltd

GUFICBIO

Gufic Biosciences Ltd

GUFICBIO
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,710 cr, stock is ranked 796
High RiskStock is 3.17x as volatile as Nifty
473.550.82% (+3.85)
473.550.82% (+3.85)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,710 cr, stock is ranked 796
High RiskStock is 3.17x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,710 cr, stock is ranked 796
High RiskStock is 3.17x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
54.538.840.02%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.926.630.50%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2024TTM
Total Revenue808.85817.35
Raw Materialssubtract389.32668.62
Power & Fuel Costsubtract17.79
Employee Costsubtract109.63
Selling & Administrative Expensessubtract103.90
Operating & Other expensessubtract40.15
Depreciation/Amortizationsubtract17.0217.09
Interest & Other Itemssubtract15.3615.91
Taxes & Other Itemssubtract29.5429.35
EPS8.598.61
DPS0.100.10
Payout ratio0.010.01

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Nov 11PDF
FY 2023

Annual report

PDF

Investor Presentation

May 29PDF
Nov 11PDF
Aug 11PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Gufic Biosciences Ltd54.688.840.02%
Sun Pharmaceutical Industries Ltd45.796.530.74%
Cipla Ltd31.234.800.82%
Mankind Pharma Ltd57.5711.50

Price Comparison

Compare GUFICBIO with any stock or ETF
Compare GUFICBIO with any stock or ETF
GUFICBIO
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding72.51%2.51%0.00%0.24%24.74%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

SepOctDec '23MarJunSep0.72%0.72%0.47%0.12%0.23%0.24%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Gufic Biosciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Motilal Oswal Small Cap Fund - Growth - Direct Plan

Growth
0.8656%1.58%-0.22%37/47 (-6)
SBI Healthcare Opportunities Fund - Growth - Direct Plan

Growth
0.8218%1.16%-0.10%28/34 (-3)
ICICI Prudential Smallcap Fund - Growth - Direct Plan

Growth
0.1566%0.08%0.08%112/117 (+2)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 17, 2024

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 17, 2024

Cash Dividend

Ex DateEx DateSep 21, 2023

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 21, 2023

Cash Dividend

Ex DateEx DateAug 24, 2022

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Aug 24, 2022

Cash Dividend

Ex DateEx DateSep 9, 2021

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 9, 2021

Cash Dividend

Ex DateEx DateNov 3, 2020

Final
Final | Div/Share: ₹0.05

Dividend/Share

0.05

Ex DateEx Date

Nov 3, 2020

News & Opinions
Corporate
Gufic BioSciences AGM scheduled

Gufic BioSciences announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Gufic BioSciences standalone net profit rises 1.16% in the June 2024 quarter

Net profit of Gufic BioSciences rose 1.16% to Rs 20.86 crore in the quarter ended June 2024 as against Rs 20.62 crore during the previous quarter ended June 2023. Sales rose 3.99% to Rs 202.81 crore in the quarter ended June 2024 as against Rs 195.02 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales202.81195.02 4 OPM %17.6518.19 - PBDT32.4232.29 0 PBT28.1128.05 0 NP20.8620.62 1 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Gufic BioSciences to hold board meeting

Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Board of Gufic BioSciences approves change in directorate

4 months agoBusiness Standard

Gufic Biosciences hits 52-week high China nod to anaesthesia API

1 year agoMoneycontrol

Stocks that will see action today: June 19, 2023

1 year agoThe Hindu Businessline

Gufic Biosciences launches locally made botox injection

1 year agoEconomic Times

Gufic Biosciences to invest ₹240 crore in new units

2 years agoThe Hindu Businessline

Gufic Biosciences launches indigenously produced Dual Chamber Bags

2 years agoBusiness Standard

Gufic Biosciences soars 14%, hits 52-week high on improved business outlook

2 years agoBusiness Standard